These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

576 related articles for article (PubMed ID: 20032445)

  • 1. Anti-glioma therapy with temozolomide and status of the DNA-repair gene MGMT.
    Fukushima T; Takeshima H; Kataoka H
    Anticancer Res; 2009 Nov; 29(11):4845-54. PubMed ID: 20032445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide.
    Hegi ME; Diserens AC; Godard S; Dietrich PY; Regli L; Ostermann S; Otten P; Van Melle G; de Tribolet N; Stupp R
    Clin Cancer Res; 2004 Mar; 10(6):1871-4. PubMed ID: 15041700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers.
    Gutenberg A; Bock HC; Brück W; Doerner L; Mehdorn HM; Roggendorf W; Westphal M; Felsberg J; Reifenberger G; Giese A
    Br J Neurosurg; 2013 Dec; 27(6):772-8. PubMed ID: 23662801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. O(6) -methylguanine-DNA methyltransferase (MGMT) promoter methylation and low MGMT-encoded protein expression as prognostic markers in glioblastoma patients treated with biodegradable carmustine wafer implants after initial surgery followed by radiotherapy with concomitant and adjuvant temozolomide.
    Lechapt-Zalcman E; Levallet G; Dugué AE; Vital A; Diebold MD; Menei P; Colin P; Peruzzy P; Emery E; Bernaudin M; Chapon F; Guillamo JS
    Cancer; 2012 Sep; 118(18):4545-54. PubMed ID: 22359215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Is the absolute value of O(6)-methylguanine-DNA methyltransferase gene messenger RNA a prognostic factor, and does it predict the results of treatment of glioblastoma with temozolomide?
    Tanaka S; Akimoto J; Narita Y; Oka H; Tashiro T
    J Neurosurg; 2014 Oct; 121(4):818-26. PubMed ID: 25105699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of MGMT promoter status in non-resectable glioblastoma after adjuvant therapy.
    Iaccarino C; Orlandi E; Ruggeri F; Nicoli D; Torricelli F; Maggi M; Cerasti D; Pisanello A; Pedrazzi G; Froio E; Crafa P; D'Abbiero N; Michiara M; Ghadirpour R; Servadei F
    Clin Neurol Neurosurg; 2015 May; 132():1-8. PubMed ID: 25723791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MGMT promoter methylation correlates with survival benefit and sensitivity to temozolomide in pediatric glioblastoma.
    Donson AM; Addo-Yobo SO; Handler MH; Gore L; Foreman NK
    Pediatr Blood Cancer; 2007 Apr; 48(4):403-7. PubMed ID: 16609952
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recurrent Glioblastoma: Combination of High Cerebral Blood Flow with MGMT Promoter Methylation Is Associated with Benefit from Low-Dose Temozolomide Rechallenge at First Recurrence.
    Kim C; Kim HS; Shim WH; Choi CG; Kim SJ; Kim JH
    Radiology; 2017 Jan; 282(1):212-221. PubMed ID: 27428890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Distinct molecular mechanisms of acquired resistance to temozolomide in glioblastoma cells.
    Happold C; Roth P; Wick W; Schmidt N; Florea AM; Silginer M; Reifenberger G; Weller M
    J Neurochem; 2012 Jul; 122(2):444-55. PubMed ID: 22564186
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MGMT gene silencing and benefit from temozolomide in glioblastoma.
    Hegi ME; Diserens AC; Gorlia T; Hamou MF; de Tribolet N; Weller M; Kros JM; Hainfellner JA; Mason W; Mariani L; Bromberg JE; Hau P; Mirimanoff RO; Cairncross JG; Janzer RC; Stupp R
    N Engl J Med; 2005 Mar; 352(10):997-1003. PubMed ID: 15758010
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [MGMT analysis in gliomas].
    Quillien V; Vauléon E; Saikali S; Lesimple T; Hamlat A; Etcheverry A; Mosser J
    Bull Cancer; 2011 Mar; 98(3):291-303. PubMed ID: 21459716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic Activation of TUSC3 Sensitizes Glioblastoma to Temozolomide Independent of MGMT Promoter Methylation Status.
    Wu Q; Berglund AE; Macaulay RJ; Etame AB
    Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37894860
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic significance of O6-methylguanine-DNA methyltransferase protein expression in patients with recurrent glioblastoma treated with temozolomide.
    Nagane M; Kobayashi K; Ohnishi A; Shimizu S; Shiokawa Y
    Jpn J Clin Oncol; 2007 Dec; 37(12):897-906. PubMed ID: 18156172
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlations between O6-methylguanine DNA methyltransferase promoter methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a prospective GICNO study.
    Brandes AA; Tosoni A; Cavallo G; Reni M; Franceschi E; Bonaldi L; Bertorelle R; Gardiman M; Ghimenton C; Iuzzolino P; Pession A; Blatt V; Ermani M;
    J Clin Oncol; 2006 Oct; 24(29):4746-53. PubMed ID: 16954518
    [TBL] [Abstract][Full Text] [Related]  

  • 15. O6-methylguanine DNA methyltransferase expression in tumor cells predicts outcome of radiotherapy plus concomitant and adjuvant temozolomide therapy in patients with primary glioblastoma.
    Watanabe R; Nakasu Y; Tashiro H; Mitsuya K; Ito I; Nakasu S; Nakajima T
    Brain Tumor Pathol; 2011 Apr; 28(2):127-35. PubMed ID: 21331613
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Benefits of interferon-β and temozolomide combination therapy for newly diagnosed primary glioblastoma with the unmethylated MGMT promoter: A multicenter study.
    Motomura K; Natsume A; Kishida Y; Higashi H; Kondo Y; Nakasu Y; Abe T; Namba H; Wakai K; Wakabayashi T
    Cancer; 2011 Apr; 117(8):1721-30. PubMed ID: 21472719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients.
    Agnihotri S; Gajadhar AS; Ternamian C; Gorlia T; Diefes KL; Mischel PS; Kelly J; McGown G; Thorncroft M; Carlson BL; Sarkaria JN; Margison GP; Aldape K; Hawkins C; Hegi M; Guha A
    J Clin Invest; 2012 Jan; 122(1):253-66. PubMed ID: 22156195
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limited role for extended maintenance temozolomide for newly diagnosed glioblastoma.
    Gramatzki D; Kickingereder P; Hentschel B; Felsberg J; Herrlinger U; Schackert G; Tonn JC; Westphal M; Sabel M; Schlegel U; Wick W; Pietsch T; Reifenberger G; Loeffler M; Bendszus M; Weller M
    Neurology; 2017 Apr; 88(15):1422-1430. PubMed ID: 28298550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma.
    Zapanta Rinonos S; Li T; Pianka ST; Prins TJ; Eldred BSC; Kevan BM; Liau LM; Nghiemphu PL; Cloughesy TF; Lai A
    J Neurooncol; 2024 Jan; 166(1):129-142. PubMed ID: 38224404
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of chemotherapy-induced DNA repair on oncolytic herpes simplex viral replication.
    Aghi M; Rabkin S; Martuza RL
    J Natl Cancer Inst; 2006 Jan; 98(1):38-50. PubMed ID: 16391370
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 29.